Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development.
about
Progress toward a universal H5N1 vaccine: a recombinant modified vaccinia virus Ankara-expressing trivalent hemagglutinin vaccine.Strategies towards universal pandemic influenza vaccines.A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferretsMF59 adjuvant: the best insurance against influenza strain diversity.Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination.A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.Long-term vaccine-induced heterologous protection against H5N1 influenza viruses in the ferret model.Combination of the immunization with the sequence close to the consensus sequence and two DNA prime plus one VLP boost generate H5 hemagglutinin specific broad neutralizing antibodies.Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.Evidence for henipavirus spillover into human populations in Africa.Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses.Extent of antigenic cross-reactivity among highly pathogenic H5N1 influenza virusesAAV ancestral reconstruction library enables selection of broadly infectious viral variants.Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines.Centralized Consensus Hemagglutinin Genes Induce Protective Immunity against H1, H3 and H5 Influenza Viruses.The Human Antimicrobial Protein Bactericidal/Permeability-Increasing Protein (BPI) Inhibits the Infectivity of Influenza A VirusA triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 virusesIdentifying antigenicity-associated sites in highly pathogenic H5N1 influenza virus hemagglutinin by using sparse learning.Cross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir.Ancient insights into uric acid metabolism in primates.Strategies to induce broadly protective antibody responses to viral glycoproteins.Efficacy of an Adenoviral Vectored Multivalent Centralized Influenza Vaccine.Broadening the H5N3 Vaccine Immunogenicity against H5N1 Virus by Modification of Neutralizing Epitopes.Challenge for One Health: Co-Circulation of Zoonotic H5N1 and H9N2 Avian Influenza Viruses in Egypt.Avian Influenza A Virus Pandemic Preparedness and Vaccine Development
P2860
Q30366891-6433753A-ADA7-414B-A624-E66FAFD8DC14Q30382226-3551BEEB-4CCB-43F1-B72A-AE44C5209650Q30399675-9FF502E5-D009-4FFC-B468-A520318A5D42Q30402018-C78155F7-662A-407A-982C-780BDBC1C2E8Q30412222-98D03874-4AC8-464E-90A8-99D08BD5BA09Q30414652-B27E1FE8-5169-4A5A-9903-8A47B9F3F442Q30420397-DEF8A830-DDD1-45B2-9B84-024AE06D53DBQ33724743-9738ED61-0D72-4DCE-9955-7188A4936150Q34309830-91CC5455-A6BD-48A1-875D-4F775BF186A6Q34541512-646A0231-94E5-4E64-92D0-25763B06C9D5Q35132253-589C008F-368B-4D64-9D31-B75F839DF393Q35273724-1581BFD4-2FAD-418F-BCFF-946DAA04E76BQ35695082-B311A384-5E95-4E06-B190-30DD8560BFF1Q35739123-A779F68D-5D53-438B-8FC8-2CDE6F865212Q35808262-41CD070C-2309-45B8-98CE-FF1994468F36Q36044173-7D9C78D2-AC09-4415-BB9B-9F0A5D6CC13FQ36086664-A7AE3380-BA18-4B90-9C30-889173D1F471Q36144055-6EB7C0D9-676D-459E-A561-38A6693623EFQ37141589-BCB31D0A-EFD7-4D96-9411-0EC4EF25CD37Q37640944-E33D3B6C-A153-4466-8EA9-E9C359BF9B2BQ39170802-9B76FB24-2C09-41B7-B26B-CA3F03B2E04AQ47105096-97862465-DBF8-46BF-9FE2-CFE39497C45BQ47558838-407BDC67-FFBF-4BB8-AFAA-5AF6E4925A8EQ52664438-75F6D010-7351-4D70-BA80-1A07BC92BE9DQ56561344-D2969176-26FF-4B38-92A1-F296BCC62A2E
P2860
Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Feasibility of reconstructed a ...... rotective vaccine development.
@ast
Feasibility of reconstructed a ...... rotective vaccine development.
@en
Feasibility of reconstructed a ...... rotective vaccine development.
@nl
type
label
Feasibility of reconstructed a ...... rotective vaccine development.
@ast
Feasibility of reconstructed a ...... rotective vaccine development.
@en
Feasibility of reconstructed a ...... rotective vaccine development.
@nl
prefLabel
Feasibility of reconstructed a ...... rotective vaccine development.
@ast
Feasibility of reconstructed a ...... rotective vaccine development.
@en
Feasibility of reconstructed a ...... rotective vaccine development.
@nl
P2093
P2860
P50
P356
P1476
Feasibility of reconstructed a ...... rotective vaccine development.
@en
P2093
Ashley Webb
Evelyn Stigger-Rosser
John Franks
Mariette F Ducatez
Subrata Barman
Yolanda Griffin
P2860
P304
P356
10.1073/PNAS.1012457108
P407
P577
2010-12-20T00:00:00Z